Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

NCT05367661 | Terminated Phase 1 DMC FDA Drug

• 1 other identifier: CHK336-01
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of CHK-336 in HV

  Incidence, nature, and severity of adverse events (AEs), adverse events of special interest (AESI), and serious adverse events (SAEs)

  Up to 28 days

Secondary Outcomes (9)

• Pharmacokinetic measure of Cmax

  Up to 17 days

• Pharmacokinetic measure of Tmax

  Up to 17 days

• Pharmacokinetic measure of AUC (0-∞)

  Up to 17 days

• Pharmacokinetic measure of AUC for up to 24 hours (AUC0-24)

  up to 17 days

• Pharmacokinetic measure of AUC for up to last measurable time point (AUC0-T)

  up to 17 days

Study Arms (4)

Part A: Healthy Volunteers: Single ascending doses

EXPERIMENTAL

Six dose groups ranging from 15mg to 500mg, under fasting condition.

Drug: CHK336; Drug: Placebo

Part A: Healthy Volunteer: Single Ascending dose under fed condition

EXPERIMENTAL

60mg under fed condition.

Drug: CHK336

Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending dose

EXPERIMENTAL

125mg, under fasting condition.

Drug: CHK336; Drug: Placebo

Part B: Healthy Volunteers: Multiple Ascending doses

EXPERIMENTAL

5 dose groups with doses ranging from 30mg to 500mg. Given daily for 14 days, under fasting condition.

Drug: CHK336; Drug: Placebo

Interventions

CHK336 DRUG

Tablet

Part A: Healthy Volunteer: Single Ascending dose under fed condition; Part A: Healthy Volunteers: Single ascending doses; Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending dose; Part B: Healthy Volunteers: Multiple Ascending doses

Placebo DRUG

Tablet

Part A: Healthy Volunteers: Single ascending doses; Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending dose; Part B: Healthy Volunteers: Multiple Ascending doses

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female adults18 to 45years old, inclusive, at the time of consent.
• Body mass index (BMI) between 19 and 32 kg/m2, inclusive, (between 30.0 and \< 40.0 kg/m2 for SAD Cohort A8) at screening.
• Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. All participants (male or female) who are of childbearing potential must agree to use highly effective contraception during the study. Female participants must continue to use highly effective contraception during the study for 30 days after the last dose of study drug. Female participants should not donate oocytes during this time. Male participants with female partners of childbearing potential must continue to use highly effective contraception during the study and for 90 days after the last dose of study drug. Male participants must agree not to donate sperm during this time. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and Day -3 as well as a negative urine pregnancy test at Day 1 (predose). WOCBP must agree to undergo a pregnancy test during the study
• Female participants not of childbearing potential must be either surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) or postmenopausal, defined as no menses for 12 months without an alternative medical cause, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the central laboratory's ranges.
• Willing and able to provide informed consent and comply with all study visits and procedures including overnight stays in the clinic
• Willing and able to comply with a pre-specified diet at least 72 hours prior to dose and throughout the study.
• Negative urine drug, tobacco, and breath alcohol test result at screening and Day-3.
• Have not used any nicotine-containing product within 3 months prior to the first study drug administration and who are willing to abstain throughout the study.

You may not qualify if:

• Any significant medical history including but not limited to hypertension, diabetes, cardiovascular disease, hemolysis, red blood cell disorders, and/or with clinically significant screening results outside the normal range for laboratory testing, vital signs, medical history, electrocardiograms (ECGs), physical examination as deemed by the investigator. Reticulocytes must be within normal range at screening and prior to dosing. Red blood cell (RBC), hemoglobin, and hematocrit must be within 5% of normal range at screening and prior to dosing.
• Evidence of chronic kidney disease (CKD) defined by an estimated glomerular filtration rate (eGFR) less than 80 mg/mL/1.73m2 based on the CKD epidemiology collaboration (EPI) equation or the presence of proteinuria at screening and prior to dosing.
• Have any known malignancy or history of malignancy, except for basal cell skin cancer that has been treated and with no evidence of recurrence for at least 3 months prior to the first study drug administration.
• History of liver disease, Gilbert's syndrome, or abnormal liver function test (AST, ALT, total bilirubin) above the normal reference range at screening and prior to dosing.
• Any active infection or acute illness within 30 days prior to the first study drug administration.
• Major surgery or significant traumatic injury occurring within 28 days prior to first dose of study drug. If major surgery occurred \> 28 days prior to first dose of study drug, individual must have recovered adequately from any toxicity and/or complications from the intervention prior to the first dose of study drug.
• Supine systolic blood pressure \<90 or \>140 mmHg, supine diastolic blood pressure \<50 or \>95 mmHg, pulse rate \<40 or \>100 beats per minute (bpm), or elevated body temperature (\>38ºC) at screening and check-in
• History or presence of a clinically significant ECG abnormalities and QTcF \>450 ms for males and \>470 ms for females, prior to dosing.
• Positive serology tests for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).
• Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication (with the exception of oral contraceptives) within 7 days prior to the first study drug administration.
• Treatment with another investigational product within 30 days prior to the first study drug administration or within the expected washout (\~5 half-lives) of the investigational product
• Prior exposure to CHK-336 (including Part A of this study).
• History or presence of alcohol abuse or drug use within 30 days prior to the first study drug administration and throughout the study
• Blood donation or significant blood loss within 60 days prior to the first study drug administration.
• Pregnancy, intent to become pregnant during the course of the study, or lactating women.

Sponsors & Collaborators

• Chinook Therapeutics, Inc.: lead

Study Sites (1)

Medpace Clinical Pharmacology Unit

Cincinnati, Ohio, 45227, United States

Location

Related Publications (1)

• Cox JH, Boily MO, Caron A, Sheng T, Wu J, Ding J, Gaudreault S, Chong O, Surendradoss J, Gomez R, Lester J, Dumais V, Li X, Gumpena R, Hall MD, Waterson AG, Stott G, Flint AJ, Moore WJ, Lowther WT, Knight J, Percival MD, Tong V, Oballa R, Powell DA, King AJ. Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment. J Am Soc Nephrol. 2025 Apr 7;36(8):1535-1547. doi: 10.1681/ASN.0000000690.

  PMID: 40193200 DERIVED

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 5, 2022
• First Posted: May 10, 2022
• Study Start: April 8, 2022
• Primary Completion: April 19, 2023
• Study Completion: April 19, 2023
• Last Updated: November 3, 2023

Record last verified: 2023-11

Locations

US (1)